login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SUMMIT THERAPEUTICS INC (SMMT) Stock News
USA
- NASDAQ:SMMT -
US86627T1088
-
Common Stock
18.66
USD
-0.57 (-2.96%)
Last: 10/29/2025, 6:19:20 PM
18.66
USD
0 (0%)
After Hours:
10/29/2025, 6:19:20 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SMMT Latest News, Press Relases and Analysis
All
Press Releases
9 days ago - By: Chartmill
Summit Therapeutics Inc (NASDAQ:SMMT) Reports Wider-Than-Expected Q3 2025 Loss
3 days ago - By: The Motley Fool
1 Monster Stock in the Making to Buy and Hold
5 days ago - By: The Motley Fool
Summit Therapeutics: A Risky Bet in the Biotech Arena?
7 days ago - By: Summit Therapeutics
Summit Therapeutics Raises $500 Million in Private Placement
9 days ago - By: Bloomberg
Summit Seeks Cancer Drug’s Approval Despite US Regulator Warning
10 days ago - By: Summit Therapeutics
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
10 days ago - By: Stocktwits
Summit Therapeutics Stock Sparks Retail Buzz After Ivonescimab Combo Cuts Cancer Progression Risk By 40%
10 days ago - By: Summit Therapeutics
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
11 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
12 days ago - By: Benzinga
An Overview of Summit Therapeutics's Earnings
13 days ago - By: Summit Therapeutics
Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
15 days ago - By: Summit Therapeutics
Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
16 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
21 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Benzinga
- Mentions:
MRVL
Alpha Buying: The 3 Stocks That Just Got This $1 Million Vote of Confidence
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Summit Therapeutics
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Summit Therapeutics
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
a month ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
a month ago - By: Stocktwits
Summit Therapeutics Stock Draws Cautious Retail Mood After Barclays ‘Underweight’ Call: ‘Added To The Biotech Graveyard’
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
2 months ago - By: Investor's Business Daily
- Mentions:
PFE
NYT
LLY
ZLAB
...
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Please enable JavaScript to continue using this application.